Interview 15 Nov 2017 Therapeutic Nanoparticle Companies Are Rare: Meet the CEO of One of Them In our last BIO Europe interview, I caught up with CEO Timm Jessen of Topas Therapeutics to hear about the company’s nanoparticles. Founded in 2013 as a spinout from Evotec, Topas Therapeutics is developing nanoparticles for a whole range of diseases and with CEO Timm Jessen at the helm. He told me the story of […] November 15, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T cells. The therapy is expected to start human tests soon. T-cell lymphoma is a form of cancer that affects the cells responsible for protecting our body against infections. Unlike it’s done with cancer types that affect other blood cells, it’s […] November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 It’s World Diabetes Day! But What is Biotech Doing to Fight the Disease? Diabetes is now a major epidemic, with 425 million people living with the condition. Luckily, biotech is working on ways to stop it in its tracks. Not only is it Antibiotic Awareness Week, but today is World Diabetes Day. This year’s theme draws attention to diabetes in women and the right to live a healthy life. […] November 14, 2017 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 Dutch RNA Firm Announces a Public Offering when its Stock is at an All-Time Low ProQR is aiming to raise funds for clinical trials on the Nasdaq despite the fact that its stock has been down for a while now. ProQR is a biotech based in Leiden that develops RNA therapies for genetic disorders, with its lead program focused on cystic fibrosis. In order to fund clinical trials, research and […] November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy Tusk Therapeutics is working on immunotherapies to ignite the immune system against cancer. The £2.5M grant will help it to accelerate their development. Tusk Therapeutics focuses on immuno-oncology to ‘harness the power’ of the immune system. One of its candidates is an antibody that targets the CD38 immune checkpoint, which is a marker of cell activation that […] November 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 14 Nov 2017 The World’s Deadliest Diseases: How is Biotech Fighting Them? With the recent outbreaks of plague in Madagascar and Ebola in West Africa, two terrifying diseases are back in the news. But these are not the only infections that are inevitably fatal if untreated, or, even worse, for which no therapy is available yet. Though mostly rare, deadly diseases are closer than you think. Plague […] November 14, 2017 - 7 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
Interview 13 Nov 2017 Where is the Money Going in Biotech? A Peek into European VC Strategy Hubert Birner, Managing Partner at TVM Capital Life Science, discusses his strategy to adapt to the European funding constraints and the areas with most potential for biotech investment. TVM Capital Life Science is a venture capital firm focusing on biotech, pharma and medtech. With over €900M under management and offices in both Munich and Montreal, TVM […] November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 Spanish Biotech Gets €2.4M to Spot Myocardial Infarction Before it’s Too Late GlyCardial Diagnostics believes it has the technology to prevent premature myocardial infarctions, 80% of which are preventable. Barcelona-based GlyCardial Diagnostics is a biotech, which spun-out from the Catalan Institute of Cardiovascular Science. The startup focuses on the development of an in vitro diagnostic device for myocardial ischemia, which is based on the detection of Apo J-Glyc in the […] November 13, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 World Antibiotic Awareness Week: Here are Biotech’s Top 5 Strategies to Overcome Resistance This week marks the WHO’s World Antibiotic Awareness Week. We had a look at some of the best work being done by biotechs to fight resistance. An estimated 154 million prescriptions for antibiotics are written each year, but up to 30% are unnecessary. The World Health Organization has set up World Antibiotic Awareness Week to tackle this. This year’s theme is […] November 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but perhaps not to the level of expectation for a company with such a high valuation. On Saturday, Immunocore presented its latest clinical results at the Society […] November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 British Biotech Gets PRIME Designation for its Brittle Bones Drug The EMA has awarded PRIME Designation to Mereo BioPharma’s osteogenesis imperfecta drug, a condition for which there is no treatment on the market. Mereo acquires, develops and commercializes therapies for patients with rare diseases. It was set up by Denise Scots-Knight, one of our top women entrepreneurs, in 2015 and already has a market cap […] November 13, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
Sponsored 13 Nov 2017 Top 5 Things to Know About Immunotherapies – A Review Immunotherapy – A big word with much meaning. There’s no use in talking about their history. The fact that immunotherapies seem to be the next big thing in biotech is reason enough to discuss them. For this purpose, we have caught up with Etienne Drouet, Vice President of Strategic Development at SynteractHCR, an international CRO. […] November 13, 2017 - 13 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email